Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact
- 1 August 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 23 (4), 320-326
- https://doi.org/10.1097/qco.0b013e3283398dc1
Abstract
This review discusses the recent findings (July 2008-January 2010) on extended-spectrum [beta]-lactamase (ESBL)-producing Escherichia coli, mainly focussed on the epidemiology and clinical impact of infections owing to this pathogen. CTX-M-producing E. coli, mainly the CTX-M-15 producers, has emerged and disseminated worldwide as an important cause of both nosocomial and community-onset infections. The clonal spread of the ST131 epidemic E. coli strain is linked not only to the CTX-M-15 pandemia but also to other ESBLs types. The most commonly reported risk factors for community-onset ESBL-producing E. coli infections are contact with healthcare centres, recent use of antimicrobial agents, and presence of comorbidities. But infections owing to ESBL-producing E. coli in patients without obvious risk factors can occur, probably related to the increase of healthy carriers colonized with this pathogen. The main significant predictor of mortality caused by ESBL-producing E. coli is inadequate initial antimicrobial therapy. Alternatives of treatment of severe ESBL-producing E. coli infections included carbapenems, amikacin, tigecycline, and [beta]-lactam/[beta]-lactamase inhibitor combinations; with some of them enough clinical evidence is lacking (tigecycline, [beta]-lactam/[beta]-lactamase inhibitor combinations). For urinary tract infections, fosfomycin and nitrofurantoin could be useful. The worldwide emergence of multiresistant ESBL-producing E. coli raises key therapeutic problems; interventions addressed to their quick detection and early appropriate antibiotic treatment and prevention are urgently needed.Keywords
This publication has 58 references indexed in Scilit:
- Molecular characterization of extended-spectrum β-lactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, IndonesiaJournal of Antimicrobial Chemotherapy, 2010
- Bacteraemia due to extended-spectrum -lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcomeJournal of Antimicrobial Chemotherapy, 2009
- Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007Antimicrobial Agents and Chemotherapy, 2009
- Molecular Characteristics of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a Cause of Community-Acquired InfectionsAntimicrobial Agents and Chemotherapy, 2009
- Molecular characterization of CTX‐M‐15‐producing clinical isolates of Escherichia coli reveals the spread of multidrug‐resistant ST131 (O25:H4) and ST964 (O102:H6) strains in NorwayAPMIS, 2009
- Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignanciesJournal of Infection, 2009
- Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15Journal of Antimicrobial Chemotherapy, 2009
- Detection of CTX-M-15, CTX-M-22, and SHV-2 Extended-Spectrum β-Lactamases (ESBLs) inEscherichia coliFecal-Sample Isolates from Pig Farms in ChinaFoodborne Pathogens & Disease, 2009
- Dominance of bla CTX-M within an Australian Extended-Spectrum β-Lactamase Gene PoolAntimicrobial Agents and Chemotherapy, 2008
- Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase- Producing Escherichia coli : Risk Factors for Inadequate Initial Antimicrobial TherapyAntimicrobial Agents and Chemotherapy, 2008